WHITE PAPERS

Gastric & Pancreatic ONC: A Year In Review

Gastric Cancer Highlights Positive readout shared in February 2023 ESMO plenary showed significant improvement in mPFS and mOS in...

GU Cancers: A Year In Review

RCC Highlights Negative results from the Phase III IMmotion010, CheckMate-914 Part A, and PROSPER trials call into question the benefit...

GYN ONC: A Year In Review

Highlights Long-term follow-up analyses from Phase III SOLO-1 (olaparib maintenance treatment in 1L BRCAm ovarian cancer) and Phase III...

Axiom Mid-Year Data Review 2022

In this report, Axiom provides a review on pivotal and paradigm shifting data from the first half of 2022 and offers our perspective on...

Insights on Cell Therapy From IO360

Executive Summary IO360 underscored the importance of the starting cell type, as the overall consensus of the superior cell type was the...

Oncology: Looking ahead

In this report, Axiom provides overview of key advances in 2021, and offer our perspective on emerging trends and their implications...

ESMO 2021 Highlights

Practice changing new data was presented at the ESMO Congress 2021. Take a look at the Axiom’s ESMO 2021 highlights.

Town Hall on ASCO 2021: Thoughts From the Think Tank

ASCO 2021 - Thoughts from the Think Tank. In this ASCO recap, we share our analysis on major updates in solid tumors including thoughts...

BREAST CANCER: A Year In Review

Highlights Results from monarchE (abemaciclib + ET) confirm the benefit of abemaciclib in in high risk, HR+ BC Although FDA ODAC voted...

AXIOM
THINK TANK